Apeloa Pharmaceutical updates on ongoing share repurchase program

Apeloa Pharmaceutical has repurchased 10,030,000 shares of its stock through a centralized bidding process, as of August 31, 2025. This represents 0.87% of the company's total share capital of 1,158,443,576 shares. The repurchases were executed at prices ranging from a high of RMB14.82 per share to a low of RMB13.62 per share, accumulating a total expenditure of RMB143,585,304, excluding transaction fees.

The company's board initially approved the repurchase plan on February 19, 2025, with an intention to use company funds for equity incentives or employee stock ownership plans. The original repurchase price limit was RMB22 per share. Following a dividend distribution in 2024, the maximum repurchase price was adjusted to RMB21.65 per share, effective from May 22, 2025.

The funding source for the repurchase was also expanded on April 25, 2025, to include "company funds and financial institution loans" instead of solely "company funds." The company confirms that all repurchases have been conducted in compliance with relevant regulations and the approved repurchase plan. Apeloa Pharmaceutical plans to continue the repurchase program within the stipulated timeframe, adhering to disclosure requirements.